No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia

Scientific Reports
Shi Thong HengTat Ming Ng

Abstract

The objective of this study was to correlate resistance mutations of extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases and virulence factors (VF) with 30-day mortality in patients treated with either piperacillin-tazobactam or carbapenems. A post-hoc analysis on 123 patients with ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia treated empirically with piperacillin-tazobactam and carbapenems was performed. Beta-lactamase resistance mutations and VF were identified by whole genome sequencing (WGS). The primary endpoint was 30-day mortality. Multivariate analyses were performed using logistic regression. WGS showed diverse multilocus sequence types (MLST) in 43 K. pneumoniae strains, while ST131 predominated in E. coli strains (57/80). CTX-M was most commonly detected (76/80 [95%] of E. coli; 39/43 [91%] of K pneumoniae.), followed by OXA (53/80 [66%] of E. coli; 34/43 [79%] of K. pneumoniae). A significant correlation was found between the number of genes encoding third-generation cephalosporin-resistant beta-lactamases and 30-day mortality (p = 0.045). The positive association was not significant after controlling for empiric carbapenem, Pitt score 3 and K. pneumoniae (OR 2.43, P = 0.0...Continue Reading

References

Oct 1, 1995·Clinical Microbiology Reviews·D M Livermore
Jun 2, 2000·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T A HekkerD M MacLaren
Jan 22, 2004·Bioinformatics·Emmanuel ParadisKorbinian Strimmer
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L PatersonVictor L Yu
Jan 28, 2005·The New England Journal of Medicine·George A Jacoby, Luisa Silvia Munoz-Price
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·George A Jacoby
Jan 16, 2007·Infection and Immunity·Matthew S LawlorVirginia L Miller
Feb 1, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L García San MiguelR Cantón
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G M RossoliniC Mugnaioli
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónT M Coque
Jun 19, 2008·Antimicrobial Agents and Chemotherapy·Christopher R BethelRobert A Bonomo
Jan 13, 2009·Clinical Microbiology Reviews·George A Jacoby
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Sep 2, 2009·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Dec 10, 2009·Antimicrobial Agents and Chemotherapy·Karen Bush, George A Jacoby
Sep 14, 2010·Current Protocols in Bioinformatics·Daniel R Zerbino
Sep 18, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·U-I WuY-C Chen
Dec 24, 2010·Journal of Clinical Microbiology·Agnès LefortUNKNOWN COLIBAFI Group
Mar 2, 2011·Transplant Infectious Disease : an Official Journal of the Transplantation Society·F BertM-H Nicolas-Chanoine
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A RogersDavid L Paterson
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Nov 8, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jesús Rodríguez-BañoUNKNOWN Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospit
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou
Apr 17, 2013·The Journal of Infection·Jesús Rodríguez-BañoUNKNOWN ESBL-REIPI Group
Jul 10, 2013·Antimicrobial Agents and Chemotherapy·Milena McLaughlinMarc H Scheetz
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Sushim Kumar GuptaJean-Marc Rolain
Mar 20, 2014·Bioinformatics·Torsten Seemann
May 13, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y HaradaK Yanagihara
Jul 2, 2014·Clinical Microbiology Reviews·Marie-Hélène Nicolas-ChanoineJean-Yves Madec
Nov 26, 2014·Genome Medicine·Michael InouyeKathryn E Holt

❮ Previous
Next ❯

Citations

Mar 30, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Ping YangYonghong Xiao
Nov 21, 2019·Indian Journal of Medical Microbiology·P A RemyaUma Sekar
Apr 1, 2019·Indian Journal of Medical Microbiology·P A RemyaUma Sekar

❮ Previous
Next ❯

Datasets Mentioned

BETA
HG941719.1
41
HS11268
PRJNA431029

Software Mentioned

FinIS
APE
Prokka
BLASTN
Opera
MLST
Velvet assembler
SRST2
Lofreq
SPSS

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.